Compare WLDS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDS | NXL |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.5M |
| IPO Year | 2021 | 2022 |
| Metric | WLDS | NXL |
|---|---|---|
| Price | $1.25 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.6K | 26.6K |
| Earning Date | 08-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $301,647.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 78.78 |
| 52 Week Low | $0.63 | $0.22 |
| 52 Week High | $6.50 | $67.20 |
| Indicator | WLDS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 32.34 |
| Support Level | $1.22 | $1.31 |
| Resistance Level | $1.48 | $5.36 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 3.00 | 47.15 |
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.